buyModerate
Joan Lordi Amble bought $122k of BAH
director at Booz Allen Hamilton Holding Corp. 930 shares at an average of $130.90, traded Feb 5, 2025, filed Feb 7, 2025.
Conviction score
48Value
$122k
930 shares
Holdings after
56,860
+2% from before
From 52-week low
+2%
low $121.55, close $123.74
From 52-week high
-30%
high $177.35, as of Feb 5, 2025
Score components
- +15RoleDirector
- +10Trade size$122k at market
- 0Relative to holdingsHoldings up 1.7%
- +18Price context2% above the 52-week low; 30% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying3 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price, last year
Rows in this filing
Every transaction in Form 4 0001443646-25-000016, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 5, 2025 | POpen-market purchase Class A Common Stock | +930 | $130.90 | $122k | 56,860 | Feb 7, 2025 |
Related signals
Other insiders at Booz Allen Hamilton Holding Corp and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 30Weak | buy | BAH Booz Allen Hamilton Holding Corp | Joan Lordi Amble director | $101k | 690 | |
| 29Weak | buy | BAH Booz Allen Hamilton Holding Corp | Joan Lordi Amble director | $294k | 2,000 | |
| 42Moderate | sell 310b5-1 | BAH Booz Allen Hamilton Holding Corp | Matthew Calderone EVP & Chief Financial Officer | $671k | 4,065 | |
| 45Moderate | sell 310b5-1 | BAH Booz Allen Hamilton Holding Corp | Nancy Laben EVP & Chief Legal Officer | $2.2M | 11,984 | |
| 36Weak | sell 310b5-1 | BAH Booz Allen Hamilton Holding Corp | Richard Crowe Executive Vice President | $700k | 4,243 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.